Clinical Trial Update: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cord blood-derived natural killer cells in combination with elotuzumab, lenalidomide, high-dose melphalan, and stem cell transplant in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasma Cell Leukemia
• Plasma Cell Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)
• Melphalan (Melphalan)
• Umbilical Cord Blood-Derived Natural Killer Cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Plasma Cell Leukemia, Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-09